Patient Guide · TARE Recovery

Recovery after TARE for liver cancer.

A realistic, sourced timeline for what to expect after Y-90 transarterial radioembolization — day of procedure, first week, post-embolisation syndrome, the REILD timing window, return to work and travel, and long-term surveillance. Drawn from the published TARE side-effect data and clinical practice at FMRI.

Dr. Ishita B. Sen, MDDirector & Chief, Nuclear Medicine · FMRI

Published 13 May 2026

Reviewed by Dr. Dharmender Malik

12 min read

Last reviewed by Dr. Dharmender Malik on 13 May 2026 · this article reflects the published primary literature and current clinical practice at FMRI Gurugram.

Introduction

TARE (transarterial radioembolization with Y-90 microspheres) is a one-day or short-stay procedure, but full recovery extends over several weeks. The day of the procedure is the easy part — patients are typically discharged within 24 hours and resume light activities within 1-2 weeks. The patterns of recovery, however, differ meaningfully between TARE and the better-known TACE: TARE produces less acute post-procedure pain but a longer-tailed fatigue profile, and the timing of any radioembolisation-induced liver disease (REILD) — when it occurs — is later than typical embolisation complications^[1]. This article walks through realistic recovery expectations drawn from the published evidence and routine practice at FMRI.

The day of the procedure — what happens

AI Overview · short answer

TARE is delivered under conscious sedation through a small catheter advanced from a femoral or radial artery puncture into the hepatic artery. The procedure itself takes 60-120 minutes. Most patients are discharged the same day or the following morning after 4-6 hours of bed rest for the femoral access site. The actual radiation delivery (Y-90 microsphere injection) is brief — most of the procedure time is spent on diagnostic angiography and super-selective catheter positioning^[2].

The day-of-procedure timeline:

Pre-procedure workup — final blood work review, vital signs, IV access, anti-emetic premedication (often ondansetron and a small dose of dexamethasone).
Conscious sedation — typically with midazolam and fentanyl; full general anaesthesia is uncommon. Patients remain awake but comfortable.
Arterial access and angiography — femoral or radial arterial puncture, then catheter advance to the hepatic artery and target branch.
Y-90 microsphere injection — typically 10-20 minutes of carefully monitored injection.
Post-injection imaging — bremsstrahlung SPECT or Y-90 PET-CT confirms distribution and informs dose verification.
Recovery in the day unit — 4-6 hours of bed rest after femoral access (less for radial). Mobilisation, light meal, vital signs checks.
Discharge — same day or next morning with written discharge instructions, anti-emetic prescription, and radiation safety guidance.

The first week — post-embolisation syndrome

Post-embolisation syndrome — a constellation of fatigue, mild nausea, low-grade fever, abdominal discomfort, and occasionally right upper quadrant pain — is the most common clinical pattern in the first 1-2 weeks after TARE. The published incidence varies from 40-70 percent depending on tumour size, Y-90 dose, and patient factors^[3].

Right upper quadrant pain — typically peaks at 24-72 hours, manageable with standard analgesia. Severe pain is uncommon and warrants assessment for non-target embolisation. Approximately 30-50% of patients report any-grade pain^[3].
Nausea / loss of appetite — affects approximately 30% of patients, mostly mild-to-moderate and resolves within 5-7 days. Anti-emetic medication is typically continued at home for 3-5 days.
Low-grade fever — temperatures up to 38.0°C in the first 3-5 days are common and reflect tumour-cell-killing inflammation; fever ≥ 38.5°C warrants assessment for infection.
Mild abdominal distension or constipation — common in the first week, related to opiate analgesia and reduced activity. Standard supportive care typically resolves it.
Mild liver function derangement — bilirubin, ALT/AST, and alkaline phosphatase commonly show modest elevation in the first 1-2 weeks that resolves spontaneously in most patients^[4].

Clinical note · TARE vs TACE recovery profile

Compared with TACE (transarterial chemoembolisation), TARE typically produces less acute post-procedure pain — patients describe the first 24-72 hours as meaningfully easier than the equivalent period after TACE. The trade-off is a longer-tailed fatigue profile: while TACE fatigue tends to resolve by 1-2 weeks, TARE fatigue often peaks at 2 weeks and gradually resolves over 4-6 weeks^[5]. For a direct comparison see our TARE vs TACE guide.

Weeks 2-4 — the fatigue tail and early response

Fatigue is the dominant symptom in weeks 2-4. It often peaks around week 2 and gradually resolves over weeks 4-6 in most patients^[6]:

Daily energy typically returns toward baseline over 3-4 weeks. Many patients return to part-time work in week 2 and full activity by weeks 3-4.
Appetite usually recovers by week 2; persistent appetite loss beyond week 3 warrants nutritional assessment.
Liver function usually normalises by week 4 if it was deranged immediately post-procedure. Persistent or progressive derangement warrants assessment for REILD.
Symptomatic improvement from tumour control — pain from tumour mass effect, jaundice from bile duct compression — often begins to be apparent in weeks 3-4 in responding patients.

REILD — what it is and when it can occur

Radioembolisation-induced liver disease (REILD) is a delayed liver dysfunction occurring 4-8 weeks after TARE in approximately 4-8 percent of patients, more common in cirrhotic patients and those receiving high cumulative liver doses^[7]:

Clinical features — jaundice (rising bilirubin), ascites, and elevated liver enzymes without disease progression on imaging.
Timing — typically presents at 4-8 weeks post-procedure, occasionally later. By the time REILD is recognised, the radiation effect on the liver has already been delivered.
Severity — ranges from mild and self-limiting to severe with hepatic failure. Cirrhotic patients are at particular risk.
Mitigation — careful patient selection, personalised dosimetry (DOSISPHERE-01 demonstrated the importance of tumour-dose precision), and avoidance of cumulative liver doses exceeding established thresholds. For more on personalised dosimetry see our TARE explainer^[8].
Treatment — supportive care, careful monitoring, and management of complications. There is no specific antidote — once REILD has developed, the radiation effect cannot be reversed.

The 4-8 week window is why post-TARE patients typically have a 6-week clinic review and blood test even when they feel well — early REILD detection allows timely supportive care.

Return to work, exercise, and travel

Most patients resume normal activities far sooner than they expect^[9]:

Sedentary or desk work — typically resumed by week 1-2, often at reduced hours initially.
Physical or manual work — typically by weeks 3-4, depending on energy levels.
Moderate exercise — gentle walking is encouraged from day 2-3 after the procedure. Higher-intensity exercise (running, weight training) is typically resumed by weeks 2-3 if energy permits.
Driving — most patients can drive safely from day 2-3 after the procedure if not on sedating analgesia. Femoral access patients should wait 48 hours before driving to allow the access site to heal.
Travel by air — generally safe from 24-48 hours after discharge. Y-90 has a half-life of 64.1 hours and patients are mildly radioactive for approximately 10-14 days post-procedure. Some airport radiation detectors may be triggered for this window; FMRI provides a treatment certificate that can be shown if needed^[10].
Sexual activity — generally safe from a few days after the procedure. Contraception is generally recommended for several weeks after the procedure; specific guidance should come from your treating team.

Radiation safety in the first week

Y-90 is a pure beta emitter with a tissue range of approximately 2.5 mm — the radiation is very locally contained, and external exposure to others is low. However, standard precautions apply for the first 5-7 days^[10]:

Maintain approximately 1 metre distance from young children and pregnant women when practical.
Sleep in a separate bed if convenient.
Practice careful hand hygiene; flush toilet twice after use; wash bedlinen separately at the first laundry cycle.
Avoid prolonged close contact in confined spaces (long car journeys, theatres) for the first few days.
By 10-14 days post-procedure (5 half-lives of Y-90), virtually all radioactivity has decayed and no further precautions are needed.

The radiation-safety guidance is conservative — actual external radiation exposure to family members from a TARE patient is far lower than the equivalent exposure from a Lu-177 PRRT patient, because Y-90 has no gamma component (only beta emission).

Long-term surveillance after TARE

Long-term surveillance after TARE addresses three concerns: (1) tumour response and progression monitoring; (2) detection of REILD or other delayed complications; (3) hepatocellular carcinoma surveillance in the post-treatment liver^[11]:

First response assessment — typically at 3 months post-procedure with contrast-enhanced CT or MRI. The mRECIST or RECICL criteria are commonly used for HCC response assessment.
Subsequent imaging — every 3 months for the first year, then every 3-6 months as clinically indicated.
Liver function — bilirubin, albumin, INR, and full liver enzyme panel at 6 weeks, then with each imaging review.
Alpha-fetoprotein (AFP) — every 3 months for HCC patients, as a complementary response and surveillance marker.
Multidisciplinary review — formal tumour-board review of response at the 3-month assessment, with discussion of additional TARE, switch to systemic therapy, transplant listing, or surveillance only.
Long-term HCC surveillance — for cirrhotic patients, lifelong ultrasound and AFP every 6 months remains standard regardless of TARE outcome.

When to call the team

Fever ≥ 38.5°C beyond the first 5 days — warrants assessment for infection or complication.
Persistent or worsening right upper quadrant pain beyond 72 hours — warrants assessment for non-target embolisation, cholecystitis, or complication.
New onset jaundice or yellow eyes in the first 8 weeks — warrants urgent assessment for REILD.
Sudden severe abdominal pain — warrants urgent assessment.
Black or tarry stools, blood in vomit, severe haematemesis — warrants urgent assessment for upper GI bleeding, particularly in cirrhotic patients with portal hypertension.
Persistent vomiting beyond 48 hours, severe dehydration, or inability to maintain oral intake.
Increasing abdominal distension — may indicate ascites accumulation suggesting REILD.

The bottom line — summary of recovery

TARE is a one-day or short-stay procedure. Most patients are discharged within 24 hours and resume light activities within 1-2 weeks.
Post-embolisation syndrome (fatigue, mild nausea, abdominal discomfort, low-grade fever) affects 40-70% of patients in the first 1-2 weeks; mostly self-limiting with supportive care^[3].
Fatigue often peaks at 2 weeks and resolves over 4-6 weeks. Most patients return to part-time work by week 2 and full activity by weeks 3-4.
REILD (radioembolisation-induced liver disease) affects 4-8% of patients, typically presenting at 4-8 weeks post-procedure with jaundice, ascites, and elevated liver enzymes. Cirrhotic patients are at higher risk^[7].
First response assessment is typically at 3 months post-procedure with contrast-enhanced CT or MRI; multidisciplinary review guides next-step decisions.
Long-term surveillance is integrated with HCC surveillance protocols and continues lifelong in cirrhotic patients.

Important

This article describes general expectations after TARE based on published data and routine practice at FMRI. Individual recovery varies based on liver disease severity, tumour distribution, Y-90 dose, and other factors. Your specific recovery plan should be discussed with your interventional radiology, hepatology, and nuclear medicine teams.

"The most common question I hear in the post-TARE clinic is — 'when will I feel back to normal?' The honest answer for most patients is 3-4 weeks, with a recognised pattern of fatigue peaking around week 2 and then gradually lifting. The reason we ask everyone to come back for a 6-week review even if they feel well is the REILD window — late liver dysfunction at 4-8 weeks is uncommon but it does happen, and catching it early matters. By 3 months, when we do the first response scan, most patients are well past the recovery and back to their lives."

Dr. Ishita B. Sen, MD · Director & Chief, Nuclear Medicine, FMRI

Post-TARE care planning · what to expect week by week

If you have a TARE procedure scheduled or have just completed one, FMRI's nuclear medicine and interventional radiology teams can walk through what to realistically expect — week by week — and when to call between scheduled follow-ups.

Discuss your TARE recovery · WhatsApp +91 8800 988936

For patients & referring clinicians

Frequently asked questions

Q01 How long does it take to recover from TARE?

Most patients are discharged within 24 hours of the procedure and resume light activities within 1-2 weeks. Post-embolisation syndrome (fatigue, mild nausea, abdominal discomfort, low-grade fever) typically resolves in the first 1-2 weeks. Fatigue often peaks at 2 weeks and gradually resolves over 4-6 weeks. Most patients return to full activity by weeks 3-4 [3][6]. Individual variation is substantial.

Q02 What is post-embolisation syndrome?

Post-embolisation syndrome is a constellation of fatigue, mild nausea, low-grade fever (up to 38.0°C), abdominal discomfort, and occasionally right upper quadrant pain in the first 1-2 weeks after TARE. Published incidence is 40-70% of patients depending on tumour size, Y-90 dose, and patient factors. It is mostly self-limiting with supportive care including anti-emetics, anti-pyretics, and analgesics [3]. Compared with TACE, TARE generally produces a milder version of post-embolisation syndrome.

Q03 Is TARE recovery more painful than TACE?

No — TARE typically produces less acute post-procedure pain than TACE. Patients commonly describe the first 24-72 hours after TARE as meaningfully easier than the equivalent period after TACE. The trade-off is a longer-tailed fatigue profile: TACE fatigue tends to resolve by 1-2 weeks, while TARE fatigue often peaks at 2 weeks and resolves over 4-6 weeks [5]. The choice between TARE and TACE depends on tumour characteristics, liver function, and treatment intent — not the recovery profile alone.

Q04 When can I return to work after TARE?

Sedentary or desk work is typically resumed by week 1-2, often at reduced hours initially. Physical or manual work is typically by weeks 3-4. Most patients work through their full TARE course (often a single procedure, sometimes followed by a second TARE to a different liver lobe) with adjustments around the recovery window [9].

Q05 What is REILD?

REILD stands for radioembolisation-induced liver disease — a delayed liver dysfunction occurring 4-8 weeks after TARE in approximately 4-8% of patients. It is characterised by jaundice, ascites, and elevated liver enzymes without disease progression on imaging. REILD is more common in cirrhotic patients and those receiving high cumulative liver doses. Careful patient selection and personalised dosimetry (DOSISPHERE-01) reduce REILD risk [7][8].

Q06 Will I be radioactive after TARE?

Yes, mildly. Y-90 has a half-life of 64.1 hours and is a pure beta emitter (no gamma). External radiation exposure to family members is low because beta radiation has a tissue range of only ~2.5 mm. Standard radiation-safety guidance applies for the first 5-7 days: maintain ~1 metre distance from young children and pregnant women, sleep in a separate bed if convenient, flush toilet twice, wash bedlinen separately at the first laundry cycle. By 10-14 days (5 half-lives), virtually all radioactivity has decayed [10].

Q07 Can I travel by air after TARE?

Travel by air is generally safe from 24-48 hours after discharge. Some airport radiation detectors may be triggered for up to 10-14 days post-procedure; FMRI provides a treatment certificate that can be shown if needed [10]. International travel within 1-2 weeks is feasible for most patients, but is best discussed with your treating team to fit with the post-procedure clinic review schedule.

Q08 When will I know if TARE worked?

The first response assessment is typically performed at 3 months post-procedure with contrast-enhanced CT or MRI, using mRECIST or RECICL criteria for HCC response assessment [11]. AFP (alpha-fetoprotein) tracking provides complementary biochemical response data in HCC patients. The radiation effect on tumours continues to mature for weeks after the procedure, which is why earlier imaging may underestimate response.

Q09 Can I exercise during TARE recovery?

Yes — gentle exercise is encouraged. Walking from day 2-3 after the procedure is recommended. Higher-intensity exercise (running, weight training) is typically resumed by weeks 2-3 if energy permits. Femoral access patients should wait 48 hours before strenuous activity to allow the access site to heal. Maintaining physical activity during cancer treatment improves quality of life and may reduce fatigue [9].

Q10 Will TARE damage my liver?

TARE is designed to spare healthy liver tissue by selectively delivering Y-90 microspheres into the hepatic artery branches feeding tumours (tumours derive their blood supply almost entirely from the hepatic artery, while normal liver derives most blood from the portal vein). Mild transient liver function derangement is common in the first 1-2 weeks. REILD — a more significant delayed liver dysfunction — affects 4-8% of patients [7]. Careful patient selection, personalised dosimetry, and avoidance of high cumulative liver doses minimise the risk of clinically significant liver damage.

Q11 Can I have TARE more than once?

Yes — a second TARE procedure to a different liver lobe or a recurrent lesion is feasible in many patients, separated by 4-12 weeks from the first procedure to allow liver function recovery and response assessment. Repeat TARE to the same hepatic territory is less common because of cumulative radiation dose concerns. The decision is made by multidisciplinary review of imaging, liver function, and treatment intent [11].

Q12 What is the long-term surveillance schedule?

Standard long-term surveillance after TARE includes: contrast-enhanced CT or MRI every 3 months for the first year, then every 3-6 months as clinically indicated; liver function tests with each imaging; AFP every 3 months for HCC patients; multidisciplinary tumour board review at key timepoints [11]. For cirrhotic patients, lifelong HCC surveillance with ultrasound and AFP every 6 months continues regardless of TARE outcome.

Citations & references

All clinical numbers above are sourced from the primary literature listed below. Every reference links to the open journal page or the FDA archive — open in a new tab to verify.

[1] Riaz A, Awais R, Salem R. Side effects of yttrium-90 radioembolization. Front Oncol. 2014;4:198. View source ↗

[2] Salem R, Lewandowski RJ, Sato KT, et al. Technical aspects of radioembolization with ⁹⁰Y microspheres. Tech Vasc Interv Radiol. 2007;10(1):12-29. View source ↗

[3] Sangro B, Carpanese L, Cianni R, et al. Survival after Y-90 resin microsphere radioembolization of HCC across BCLC stages. Hepatology. 2011;54(3):868-878. View source ↗

[4] Sangro B, Bilbao JI, Boan J, et al. Radioembolization using ⁹⁰Y-resin microspheres for advanced HCC. Int J Radiat Oncol Biol Phys. 2006;66(3):792-800. View source ↗

[5] Salem R, Gordon AC, Mouli S, et al. Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in HCC. Gastroenterology. 2016;151(6):1155-1163. View source ↗

[6] Salem R, Lewandowski RJ. Chemoembolization and radioembolization for hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2013;11(6):604-611. View source ↗

[7] Sangro B, Gil-Alzugaray B, Rodriguez J, et al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer. 2008;112(7):1538-1546. View source ↗

[8] Garin E, Tselikas L, Guiu B, et al. Personalised vs standard dosimetry approach of SIRT in locally advanced HCC (DOSISPHERE-01). Lancet Gastroenterol Hepatol. 2021;6(1):17-29. View source ↗

[9] Mishra SI, Scherer RW, Geigle PM, et al. Exercise interventions on health-related quality of life for cancer survivors. Cochrane Database Syst Rev. 2012;(8):CD007566. View source ↗

[10] IAEA. Safety in Nuclear Medicine: A Practical Guide. IAEA Safety Standards Series. 2014. View source ↗

[11] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of HCC. J Hepatol. 2018;69(1):182-236. View source ↗

[12] Salem R, Johnson GE, Kim E, et al. Y-90 Radioembolization for Solitary, Unresectable HCC: The LEGACY Study. Hepatology. 2021;74(5):2342-2352. View source ↗

[13] Mahnken AH, Spreafico C, Maleux G, et al. Standards of practice in transarterial radioembolization. Cardiovasc Intervent Radiol. 2013;36(3):613-622. View source ↗

[14] Kennedy A, Nag S, Salem R, et al. Recommendations for radioembolization of hepatic malignancies. Int J Radiat Oncol Biol Phys. 2007;68(1):13-23. View source ↗

[15] Salem R, Padia SA, Lam M, et al. Clinical and dosimetric considerations for Y90. Eur J Nucl Med Mol Imaging. 2019;46(8):1695-1704. View source ↗

[16] Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, Staging, and Management of HCC: 2018 AASLD Practice Guidance. Hepatology. 2018;68(2):723-750. View source ↗

[17] Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: 2022 update. J Hepatol. 2022;76(3):681-693. View source ↗

[18] Wasan HS, Gibbs P, Sharma NK, et al. First-line SIRT plus chemotherapy vs chemotherapy alone in CRC liver metastases (FOXFIRE-SIRFLOX-FOXFIRE-Global). Lancet Oncol. 2017;18(9):1159-1171. View source ↗

[19] Lhommel R, Goffette P, Van den Eynde M, et al. Y-90 TOF PET scan demonstrates high-resolution biodistribution after liver SIRT. Eur J Nucl Med Mol Imaging. 2009;36(10):1696. View source ↗

[20] Cremonesi M, Chiesa C, Strigari L, et al. Radioembolization of hepatic lesions from a radiobiology and dosimetric perspective. Front Oncol. 2014;4:210. View source ↗

[21] Vouche M, Lewandowski RJ, Atassi R, et al. Radiation lobectomy: time-dependent analysis of future liver remnant volume. J Hepatol. 2013;59(5):1029-1036. View source ↗

[22] Lewandowski RJ, Donahue L, Chokechanachaisakul A, et al. Y-90 radiation lobectomy: outcomes after surgical resection. J Surg Oncol. 2016;114(1):99-105. View source ↗

[23] Padia SA, Lewandowski RJ, Johnson GE, et al. Radioembolization of Hepatic Malignancies: Quality Improvement Guidelines. J Vasc Interv Radiol. 2017;28(11):1457-1473. View source ↗

[24] Mosconi C, Solaini L, Vara G, et al. TACE and TARE for Unresectable Intrahepatic Cholangiocarcinoma. Cardiovasc Intervent Radiol. 2020;43(11):1644-1655. View source ↗

[25] Memon K, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for neuroendocrine liver metastases. Int J Radiat Oncol Biol Phys. 2012;83(3):887-894. View source ↗

[26] Vilgrain V, Pereira H, Assenat E, et al. SIRT vs sorafenib in advanced HCC (SARAH). Lancet Oncol. 2017;18(12):1624-1636. View source ↗

[27] Chow PKH, Gandhi M, Tan SB, et al. SIRT vs Sorafenib in Asia-Pacific HCC (SIRveNIB). J Clin Oncol. 2018;36(19):1913-1921. View source ↗

[28] Westcott MA, Coldwell DM, Liu DM, et al. Y-90 radiolabeled resin and glass microspheres development. Adv Radiat Oncol. 2016;1(4):351-364. View source ↗

[29] Boas FE, Bodei L, Sofocleous CT. Radioembolization of CRC Liver Metastases. J Nucl Med. 2017;58(Suppl 2):104S-111S. View source ↗

[30] Salem R, Mazzaferro V, Sangro B. Y-90 radioembolization for HCC: biological lessons, challenges, perspectives. Hepatology. 2013;58(6):2188-2197. View source ↗

[31] Llovet JM, Castet F, Heikenwalder M, et al. Immunotherapies for HCC. Nat Rev Clin Oncol. 2022;19(3):151-172. View source ↗

[32] Bilbao JI, Reiser MF, eds. Liver Radioembolization with ⁹⁰Y Microspheres. Springer Medical Radiology series. 2014. View source ↗

About the Author

Dr. Ishita B. Sen

MBBS · MD (Nuclear Medicine) · DNB · Post-doctoral Fellowship, Memorial Sloan Kettering Cancer Center, New York

Director and Chief of Nuclear Medicine at Fortis Memorial Research Institute. Co-founder of Theranostic Physicians Private Limited (TPPL). Two decades of clinical practice in PSMA imaging and PSMA-directed radioligand therapy, with one of the largest Indian institutional experiences in Lu-PSMA.

Full profile → All publications Book a consult